Review finds ADHD drugs may ease perimenopause brain fog and improve daily focus, but objective cognition gains remain unclear; larger safety and efficacy studies needed.
|Slideshows|June 29, 2017
Psychiatric Questions, Queries, and Quarrels
In psychiatry, hot debates abound if you just look around-and if this Special Report collection is any indication, the result is a balance of opinion and civility made richer by virtue of opposing views.
Advertisement
Advertisement
Related to this article
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
APSARD is preparing US adult ADHD guidelines, delivering long-awaited screening, diagnosis, and treatment recommendations as experts discuss the upcoming release.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
2
Improving but Not Feeling It: Anticipatory Anhedonia and Cognition
3
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
4
Evidence-Based Ethical Principles for Long-Acting Injectable Antipsychotic Use
5